<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934114</url>
  </required_header>
  <id_info>
    <org_study_id>D1025</org_study_id>
    <nct_id>NCT01934114</nct_id>
  </id_info>
  <brief_title>NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo</brief_title>
  <official_title>NIR (Near Infrared Spectral Tomography)Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether an experimental alternative imaging method,&#xD;
      Near Infrared Spectroscopy (abbreviated as NIR), can be used with a controlled respiratory&#xD;
      system to examine the breasts for cancer. The NIR system uses light beams to produce an image&#xD;
      or picture of the inside of the breast. The respiratory system will help researchers get more&#xD;
      information about the breast tissue by changing the amount of oxygen the tissue receives&#xD;
      during NIR imaging.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantify tumor oxygenation response in patients imaged.Determine capability of imaging dynamic to capture oxygenation changes within the tumor.</measure>
    <time_frame>18 weeks approximately</time_frame>
    <description>Analyze captured data from use of dynamic NIR topographic oximetry (in a cohort of women receiving conventional anthracycline/taxane based adjuvant chemotherapy).Quantify pathological and clinical outcomes.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Under Treatment</arm_group_label>
    <description>Patients with locally advanced breast cancer, defined as being clinically appropriate for neoadjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Cohort</arm_group_label>
    <description>Healthy female volunteers with breast size and epithelial integrity adequate to allow NIR imaging exams</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Females with locally advanced breast cancer defined as being clinically appropriate for&#xD;
        neoadjuvant therapy and healthy volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NORMAL cohort&#xD;
&#xD;
               1. Breast size and epithelial integrity adequate to allow NIR imaging exams&#xD;
&#xD;
               2. No serious associated psychiatric illnesses&#xD;
&#xD;
               3. Female, ≥25 and &lt;76 years old&#xD;
&#xD;
               4. Written informed consent&#xD;
&#xD;
          -  UNDER TREATMENT cohort&#xD;
&#xD;
               1. Locally advanced breast cancer, with or without metastatic disease, defined as&#xD;
                  being clinically appropriate for neoadjuvant therapy&#xD;
&#xD;
               2. Breast size and epithelial integrity adequate to allow NIR imaging exams&#xD;
&#xD;
               3. No serious associated psychiatric illnesses&#xD;
&#xD;
               4. Female, ≥25 and &lt;76 years old&#xD;
&#xD;
               5. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  both cohorts&#xD;
&#xD;
               1. Pre-existing respiratory conditions:&#xD;
&#xD;
                    1. severe chronic obstructive pulmonary disease (including chronic bronchitis&#xD;
                       and/or emphysema)&#xD;
&#xD;
                    2. Other respiratory or lung conditions which would place the patient at risk&#xD;
&#xD;
                    3. presence of any other significant cardiac or pulmonary symptoms, such as&#xD;
                       moderate or severe dyspnea on exertion, orthopnea, or paroxysmal nocturnal&#xD;
                       dyspnea&#xD;
&#xD;
               2. Congestive heart failure&#xD;
&#xD;
               3. Intolerance of hyperoxia or hypercarbia as delivered by the RespirAct breathing&#xD;
                  circuit&#xD;
&#xD;
               4. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

